Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | PDXK | O00764 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387458 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL516267 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL9232006 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL5346682 | 0.84 | KDM4E (0.61) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL11034354 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL31208064 | 0.81 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL31190161 | 0.81 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL405403 | 0.80 | HPGD (0.63) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pirisudanol SCHEMBL49261 | 0.80 | ALDH1A1 (0.49) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL483438 | 0.79 | DGKA (0.43) | KDM4EALDH1A1HPGDHSD17B10HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654231-B1 | CONJUGATE COMPOUNDS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE OR FOR TREATMENT OF SEIZURE DISORDERS | DPHARM LTD (IL) | 2012-02-01 | — | — | EP | disclosed |
| US-7745426-B2 | Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders | D-PHARM LTD. (IL) | 2010-06-29 | — | — | US | disclosed |
| WO-2009043096-A1 | IMPROVED METHOD FOR MUTAGENESIS | ARANA THERAPEUTICS (VIC) PTY LTD (AU) | 2009-04-09 | — | — | WO | disclosed |
| EP-1654231-A4 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS | DPHARM LTD (IL) | 2009-03-11 | — | — | EP | disclosed |
| CN-1867550-A | Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders | DPHARM LTD (IL) | 2006-11-22 | — | — | CN | disclosed |
| US-20060235000-A1 | Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders | D-PHARM LTD. (IL) | 2006-10-19 | — | — | US | disclosed |
| EP-1558745-A4 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES | EVOGENIX PTY LTD (AU) | 2006-08-30 | — | — | EP | disclosed |
| EP-1654231-A2 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS | D-Pharm Ltd. (IL) | 2006-05-10 | — | — | EP | disclosed |
| EP-1558745-A1 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES | Evogenix Pty Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005016228-A2 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS | D-PHARM LTD. (IL) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004039995-A1 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES | EVOGENIX PTY LTD (AU) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235000-A1 | Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders | PNPO, CYP2B6, CHRNA6 | KDM4E 581/4885ALDH1A1 1711/4885HPGD 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.